PARIJS –(BUSINESS WIRE)–Kandidaat-geneesmiddel PXT3003, in een Fase 3 studie voor de behandeling van Charcot-Marie-Tooth ziekte type 1A, zal worden belicht op zes posters en twee mondelinge presentaties.
Kandidaat-geneesmiddel PXT864, in klinische ontwikkeling voor de behandeling van de ziekte van Alzheimer, zal worden belicht in twee posters en drie mondelinge presentaties

Regelgevend nieuws:

Pharnext SA (FR0011191287 – ALPHA) (Parijs:ALPHA), een biofarmaceutisch bedrijf dat een pioniersrol vervult in een nieuwe benadering van de ontwikkeling van innovatieve geneesmiddelencombinaties gebaseerd op Big Data Genomics en artificiële intelligentie, kondigt vandaag haar aanstaande deelname aan vijf internationale wetenschappelijke conferenties aan in juni en juli 2018 in heel Europa en de Verenigde Staten.

Pharnext to Present Latest Scientific Data on its Two Lead Assets at Several International Scientific Conferences

PARIS–(BUSINESS WIRE)–

• Drug candidate PXT3003, in a Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A, will be highlighted in six posters and two oral presentations
• Drug candidate PXT864, in clinical development for the treatment of Alzheimer’s disease, will be highlighted in two posters and three oral presentations

Regulatory News:

Pharnext SA (FR0011191287 – ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced its upcoming participation in five international scientific conferences in June and July 2018 throughout Europe and the United States.

Pharnext will share the latest scientific and clinical data regarding PXT3003, a drug candidate which is currently being evaluated in an ongoing international pivotal Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A. Pharnext will also illustrate the benefits of its disruptive R&D approach PLEOTHERAPY™ in developing drug combinations, and discuss the Company’s Phase 2 trial of PXT864 for the treatment of Alzheimer’s disease.

The company will attend the following events:

European Academy of Neurology (EAN) congress
June 16-18, 2018 in Lisbon, Portugal

Two ePosters (oral communications)

#EPR1170		A multicenter, double-blind, placebo-controlled, pivotal phase III study (PLEO-CMT) of a fixed combination of baclofen, naltrexone and sorbitol (PXT3003) for Charcot-Marie-Tooth Disease Type 1A (CMT1A).
Presenter:		Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France
Room		Session EPR122 / Screen B12
Date/Time		June 16, 2018, 13:30 – 14:15 CEST

#EPR1007		Double-blind argument for a synergistic therapeutic effect of a fixed low-dose combination of acamprosate and baclofen in Alzheimer’s disease.
Presenter:		Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France
Room		Session EPR101 / Screen A1
Date/Time		June 16, 2018, 13:30 – 14:15 CEST

International Congress on Neuromuscular Diseases (ICNMD)
July 6-10, 2018 in Vienna, Austria

Two Posters

#545		Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats.
Authors		T. Prukop et al.
Room		Mezzanine Floor Gallery and Foyers
Date/Time		July 8, 2018, 5:15pm – 6:30pm CEST

#728		Baclofen, naltrexone and sorbitol all contribute to PXT3003-induced myelination in CMT1A DRG co-cultures.
Authors		N. Cholet et al.
Room		Session Room 1
Date/Time		July 8, 2018, 5:15pm – 6:30pm CEST

Innovations and State of the Art In Dementia Research meeting (ISADR)
July 16-18, 2081 in Valencia, Spain

Two Oral Communications

		Cmax-based synergistic therapeutic effect on cognitive disability in mild Alzheimer’s disease after 36 weeks treatment with baclofen and acamprosate.
Presenter:		Prof Jacques Touchon, MD, PhD, Faculteì de Meìdecine de Montpellier, France
Date/Time		July 16, 2018, 11:35am – 11:55am CEST

		A potential tri-therapy for Alzheimer’s disease.
Presenter:		Dr Rodolphe Hajj, PhD, Chief Pharmacology Officer, Pharnext, France
Date/Time		July 16, 2018, 12:55pm – 1:15pm CEST

Peripheral Nerve Society (PNS) congress
July 22-25, 2018 in Baltimore, US

One Oral Communication

		Status of the Pivotal Phase III Study of PXT3003 for Charcot-Marie-Tooth Type 1A disease (CMT1A).
Presenter:		Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France
Date/Time		July 23, 2018, 2.45pm – 3.00pm EST

Four Posters

#20		Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats.
Authors		R. Hajj et al.
Session		Session 1
Date/Time		July 22, 2018

#45		Status of the Pivotal Phase III Study of PXT3003 for Charcot-Marie-Tooth Type 1A disease (CMT1A)
Authors		R. Goedkoop et al.
Session		Session 2
Date/Time		July 23, 2018

#85		Synergy of baclofen, naltrexone and sorbitol (PXT3003) in Charcot-Marie-Tooth Type 1A (CMT1A)
Authors		J. Laffaire et al
Session		Session 2
Date/Time		July 23, 2018

#1	Baclofen, naltrexone and sorbitol all contribute to PXT3003-induced myelination in CMT1A DRG co-cultures
Authors	R. Hajj et al.
Session	Session 3
Date/Time	July 24, 2018

Alzheimer’s Association International Conference (AAIC)
July 22-26, 2018 in Chicago, US

Two Posters

#P1-061		Double-blind argument for a synergistic therapeutic effect of a fixed low-dose combination of acamprosate and baclofen in Alzheimer’s Disease
Authors		J-M Orgogozo et al
Session		Session P1-01 / Hall F1
Date/Time		July 22, 2018, 9:30am – 4:15pm EST

#P3-042		PXT864 combination restores cognitive deficits of Alzheimer’s mice, even in animals with advanced disease that lost responsiveness to donepezil.
Authors		A. Brureau et al.
Session		Session P3-02, Hall F1
Date/Time		July 24, 2018, 9:30am – 4:15pm EST

If you are interested in meeting the Pharnext team during either of these events or if you need more information about Pharnext’s participation, please send an email to contact@pharnext.com

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.

Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit http://www.pharnext.com/

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20180611005795/en/

Contacts

Pharnext
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
contact@pharnext.com
or
Financial Communication (France)
Actifin
Stéphane Ruiz, +33 (0)1 56 88 11 15
sruiz@actifin.fr
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
matthew@sternir.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Media Relations (Europe)
Ulysse Communication
Bruno Arabian, +33 (0)1 81 70 96 30
barabian@ulysse-communication.com
or
Media Relations (U.S.)
RooneyPartners
Kate L. Barrette, +1 212 223 0561
kbarrette@rooneyco.com